Standard Biotools Inc Total Liabilities
Standard Biotools Inc total liabilities. Based on the latest financial reports, Standard Biotools Inc (LAB) has total liabilities worth $87.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LAB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Standard Biotools Inc (2006–2025)
Total liabilities of Standard Biotools Inc from 2006 to 2025. This chart illustrates how Standard Biotools Inc's total liabilities have evolved over time, based on quarterly financial data. Explore LAB long-term investment intensity to see how much of total assets are deployed in long-term investments.
Standard Biotools Inc Competitors by Total Liabilities
The table below lists competitors of Standard Biotools Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Invercap
SN:INVERCAP
|
Chile | CL$3.34 Billion |
|
Hiron-Trade Investments & Industrial Buildings Ltd
TA:HRON
|
Israel | ILA349.64 Million |
|
Stille AB
ST:STIL
|
Sweden | Skr362.30 Million |
|
ICBC Turkey Bank AS
IS:ICBCT
|
Turkey | TL93.98 Billion |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
China | CN¥1.09 Billion |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
China | CN¥130.08 Million |
|
Global Partner Acquisition II Corp
NASDAQ:GPAC
|
USA | $17.59 Million |
|
El-Mor Electric Installation & Services 1986 Ltd
TA:ELMR
|
Israel | ILA404.39 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Standard Biotools Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Standard Biotools Inc's balance sheet.
Liquidity & Leverage Metrics
Standard Biotools Inc Total Liabilities Ratios Explained
Standard Biotools Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Standard Biotools Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Standard Biotools Inc (2006–2025)
The table below shows the annual total liabilities of Standard Biotools Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $143.46 Million | +2.02% |
| 2024-12-31 | $140.62 Million | -70.15% |
| 2023-12-31 | $471.12 Million | -0.14% |
| 2022-12-31 | $471.78 Million | +161.20% |
| 2021-12-31 | $180.62 Million | -2.74% |
| 2020-12-31 | $185.71 Million | +67.00% |
| 2019-12-31 | $111.20 Million | -51.97% |
| 2018-12-31 | $231.53 Million | -9.70% |
| 2017-12-31 | $256.42 Million | +1.29% |
| 2016-12-31 | $253.16 Million | -1.17% |
| 2015-12-31 | $256.16 Million | -0.38% |
| 2014-12-31 | $257.14 Million | +1198.88% |
| 2013-12-31 | $19.80 Million | +51.41% |
| 2012-12-31 | $13.07 Million | -41.70% |
| 2011-12-31 | $22.43 Million | -89.52% |
| 2010-12-31 | $213.97 Million | +3.98% |
| 2009-12-31 | $205.77 Million | +7.91% |
| 2008-12-31 | $190.69 Million | +3.02% |
| 2007-12-31 | $185.11 Million | +29.75% |
| 2006-12-31 | $142.66 Million | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more